<p>
    Hepatitis Virus Positive Donors:
</p>
<ul>
    <li class="ck-list-marker-bold" data-list-item-id="ec05fe2e41e12edea15ecfe8a153d7611">
        <strong>HCV-Positive Donors</strong>
        <ul>
            <li data-list-item-id="e9ba4ae2c758d2eea64da2097f0c16c38">
                <strong>Transmission Risk</strong>: Low with NAT-negative donors.
            </li>
            <li data-list-item-id="eca030d4ccd05eaabeb7f113a6031764f">
                <strong>Pre-Transplant Biopsy</strong>: Required to rule out fibrosis ≥F2.
            </li>
            <li data-list-item-id="e09217085b5b34a32974da120c59bb15b">
                <strong>Post-Transplant Monitoring</strong>: HCV-RNA at weeks 2 and 12.
            </li>
            <li data-list-item-id="ef7e98caeb5e8dd7607a9c1c4ff28079d">
                <strong>Antiviral Therapy</strong>: If RNA positive at both time points, initiate therapy beyond 3 months (Epclusa or Maviret for 12 weeks).
            </li>
        </ul>
    </li>
    <li data-list-item-id="ecf30926ba2ff53031bc6f11e0ee6d4b4">
        <strong>HBV-Positive Donors</strong>: Pre-Transplant Biopsy: Required to assess for fibrosis ≥F2
    </li>
    <li data-list-item-id="e078c93d48f343375193bbc909e0b79fe">
        <strong>HCC Surveillance</strong>: Annual liver ultrasound and AFP.
    </li>
</ul>
<p>
    &nbsp;
</p>
<p>
    <strong>Donor Profiles:</strong>
</p>
<p>
    1. <strong>anti-HBc+, HBsAg- Donors:</strong>
</p>
<ul>
    <li data-list-item-id="ea1d5849efc82519a22afe7b5a154d4b3">
        Preferred for older recipients.
    </li>
    <li data-list-item-id="e4660573b866530b578723b86109d8a67">
        No HBIG needed.
    </li>
    <li data-list-item-id="e5db4e2ecddc508e1386766268760f46d">
        Follow NUC-based prophylaxis:
        <ul>
            <li data-list-item-id="eecd84a41b07da432453de9b6886433c7">
                <strong>anti-HBc+ recipient</strong>: Start NUCs; may wean in anti-HBs+ recipients.
            </li>
            <li data-list-item-id="ef0283d9e675f48ebcb49edfc891010ba">
                <strong>Vaccinated recipient (anti-HBs+ only)</strong>: Start NUCs; may wean if titers stable.
            </li>
            <li data-list-item-id="e3371c4638ac951c622d893ef70b14396">
                <strong>Seronegative recipients</strong>: Start NUCs; vaccinate after 3–6 months.
            </li>
        </ul>
    </li>
</ul>
<p>
    2. <strong>HBsAg+ Donors</strong>: Not currently allocated by TGLN.
</p>
<p>
    3. <strong>HBV/HDV+ Donors</strong>: Not accepted due to high risk of early refibrosis.
</p>
<p>
    &nbsp;
</p>
<ul>
    <li data-list-item-id="e4fdddcf36739489217bed50ff59fb45a">
        Surgical Liver Procurement and Preservation
    </li>
    <li data-list-item-id="e748402936ca6d387a38bcf4c01505b61">
        Processes?
    </li>
    <li data-list-item-id="eac20dcd30fe96811847c139eadc3a711">
        Calculators
    </li>
    <li data-list-item-id="e0151d1297c64de539936c39854937ce2">
        Tissue Collection
    </li>
    <li data-list-item-id="e3b2b65152b85cb0d37bff38c72cb1713">
        &nbsp;
    </li>
</ul>
<p>
    References:
</p>
<ul>
    <li class="ck-list-marker-italic" data-list-item-id="efd2feebdd0e55997781a8bf0740dd512">
        <i>Living Liver Donor CT-MR Review Form</i>
    </li>
    <li class="ck-list-marker-italic" data-list-item-id="e111eede22364d78d8e30f3e367ea46a4">
        <i>Viral hepatitis Transplant SOP&nbsp;</i>
    </li>
</ul>